On November 7, Arkuda Therapeutics announced the completion of a $44 million Series A round of financing, led by Atlas Venture and Pfizer Ventures, and Tekla Capital Management and BioInnovation Capital. The company will use the funds to promote its treatment of frontotemporal dementia (FTD) drugs through Phase I… Continue Reading Targeting granule protein precursors to prevent dementia, this company is spotlighted by Pfizer

  The prototype of the best-selling book “The Billion-Dollar Molecule” in the pharmaceutical industry is Vertex. The company, which was founded in 1989, started with $10 million in funds and can be said to be a dark horse enterprise in the pharmaceutical industry. Vertex has created three drugs with annual… Continue Reading “The Billion-Dollar Molecule” prototype Vertex’s “Next City”

  On April 25, Lilly announced that it is advancing the global withdrawal of the new soft tissue sarcoma drug Lartruvo (olaratumab). Lilly’s decision was mainly due to the fact that in the large phase III ANNOUNCE study after marketing, olaratumab failed to show survival benefit in both the treated… Continue Reading Lilly’s soft tissue sarcoma drug Olaratumab will withdraw from the world

  When BMS paid for the acquisition of Celgene in early January, investors who were not optimistic about the deal considered a big risk that Celgene’s blockbuster drug Revlimid faced a patent challenge and sales would shrink sharply. But a recent US Patent and Trademark Office (PTO) decision has given… Continue Reading The lenalidomide patent challenge threatens to be temporarily lifted! Dr. Reddy’s three patent challenges were invalidated

  On February 6, the FDA approved the introduction of Cablivi (caplacizumab-yhdp) injection developed by Sanofi’s subsidiary Ablynx for plasma exchange and immunosuppressive therapy for adult acquired thrombotic thrombocytopenic purpura (aTTP). On September 3, 2018, the European Union has approved the application for the listing of Cablivi for this indication.… Continue Reading FDA approves first Nanobody to treat acquired thrombotic thrombocytopenic purpura

  On January 18th, Celgene announced a partnership with Kyn Therapeutics, a startup that is committed to developing immune systems against cancer. Kyn is an investment by Atlas Venture and OrbiMed and is headquartered in Boston. Celgene will pay Kyn a down payment of $80 million and an undisclosed equity… Continue Reading Celgene’s heavy trading

  In recent years, the number of new drugs approved by the FDA has reached record highs. With this situation, the pricing of specialty drugs is getting higher and higher, and the prices of some new technology therapies that have not yet been approved are even more jaw-dropping. According to… Continue Reading The 20 most expensive drugs in the US pharmacy retail price in 2018

  In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.

  On November 30, Pfizer announced a settlement with AbbVie on a worldwide patent litigation against adalimumab biosimilars. Under the agreement, in the European market, Pfizer’s adalimumab biosimilars will be available for sale upon approval by the EMA. However, in the US market, Pfizer needs to market adalimumab biosimilars on… Continue Reading Pfizer and AbbVie reach a settlement, delaying the launch of Humira-like drugs in the US

  Last year, the rumor that Pascal Soriot had to change to the CEO of Teva was very rampant, and the reasons for his departure were constant. Pascal Soriot himself declined to comment directly on the matter and later sent an internal memo to the staff, urging them to continue… Continue Reading Rumors: AstraZeneca will replace the CEO? Successor candidates may be generated internally